IMMUNE NETWORK

The Korean Association of Immunobiologists (대한면역학회)
권호 표지
DOI QR코드

DOI QR Code

Baculovirus-based Vaccine Displaying Respiratory Syncytial Virus Glycoprotein Induces Protective Immunity against RSV Infection without Vaccine-Enhanced Disease

  • Kim, Sol (Division of Life & Pharmaceutical Sciences, and Center for Cell Signaling & Drug Discovery Research, Ewha Womans University) ;
  • Chang, Jun (Division of Life & Pharmaceutical Sciences, and Center for Cell Signaling & Drug Discovery Research, Ewha Womans University)
  • Received : 2011.12.12
  • Accepted : 2012.01.08
  • Published : 2012.02.29
Download PDF
⟨ Previous Next ⟩

Abstract

Background: Respiratory syncytial virus (RSV) is a major cause of severe lower respiratory tract diseases in infancy and early childhood. Despite its importance as a pathogen, there is no licensed vaccine against RSV yet. The attachment glycoprotein (G) of RSV is a potentially important target for protective antiviral immune responses. Recombinant baculovirus has been recently emerged as a new vaccine vector, since it has intrinsic immunostimulatory properties and good bio-safety profile. Methods: We have constructed a recombinant baculovirus-based RSV vaccine, Bac-RSV/G, displaying G glycoprotein, and evaluated immunogenicity and protective efficacy by intranasal immunization of BALB/c mice with Bac-RSV/G. Results: Bac-RSV/G efficiently provides protective immunity against RSV challenge. Strong serum IgG and mucosal IgA responses were induced by intranasal immunization with Bac-RSV/G. In addition to humoral immunity, G-specific Th17- as well as Th1-type T-cell responses were detected in the lungs of Bac-RSV/G-immune mice upon RSV challenge. Neither lung eosinophilia nor vaccine-induced weight loss was observed upon Bac-RSV/G immunization and subsequent RSV infection. Conclusion: Our data demonstrate that intranasal administration of baculovirus-based Bac-RSV/G vaccine is efficient for the induction of protection against RSV and represents a promising prophylactic vaccination regimen.

Keywords

References

  1. Falsey AR, Hennessey PA, Formica MA, Cox C, Walsh EE: Respiratory syncytial virus infection in elderly and high-risk adults. N Engl J Med 352;1749-1759, 2005. https://doi.org/10.1056/NEJMoa043951
  2. Falsey AR, Walsh EE: Respiratory syncytial virus infection in adults. Clin Microbiol Rev 13;371-384, 2000. https://doi.org/10.1128/CMR.13.3.371-384.2000
  3. Robinson RF: Impact of respiratory syncytial virus in the United States. Am J Health Syst Pharm 65(23 Suppl 8);S3-S6, 2008.
  4. Glezen WP, Greenberg SB, Atmar RL, Piedra PA, Couch RB: Impact of respiratory virus infections on persons with chronic underlying conditions. JAMA 283;499-505, 2000. https://doi.org/10.1001/jama.283.4.499
  5. Fulginiti VA, Eller JJ, Sieber OF, Joyner JW, Minamitani M, Meiklejohn G: Respiratory virus immunization. I. A field trial of two inactivated respiratory virus vaccines; an aqueous trivalent parainfluenza virus vaccine and an alum-precipitated respiratory syncytial virus vaccine. Am J Epidemiol 89;435-448, 1969. https://doi.org/10.1093/oxfordjournals.aje.a120956
  6. Openshaw PJ, Clarke SL, Record FM: Pulmonary eosinophilic response to respiratory syncytial virus infection in mice sensitized to the major surface glycoprotein G. Int Immunol 4;493-500, 1992. https://doi.org/10.1093/intimm/4.4.493
  7. Varga SM, Wang X, Welsh RM, Braciale TJ: Immunopathology in RSV infection is mediated by a discrete oligoclonal subset of antigen-specific CD4(+) T cells. Immunity 15;637-646, 2001. https://doi.org/10.1016/S1074-7613(01)00209-6
  8. Tebbey PW, Hagen M, Hancock GE: Atypical pulmonary eosinophilia is mediated by a specific amino acid sequence of the attachment (G) protein of respiratory syncytial virus. J Exp Med 188;1967-1972, 1998. https://doi.org/10.1084/jem.188.10.1967
  9. Yu JR, Kim S, Lee JB, Chang J: Single intranasal immunization with recombinant adenovirus-based vaccine induces protective immunity against respiratory syncytial virus infection. J Virol 82;2350-2357, 2008. https://doi.org/10.1128/JVI.02372-07
  10. Blissard GW, Rohrmann GF: Baculovirus diversity and molecular biology. Annu Rev Entomol 35;127-155, 1990. https://doi.org/10.1146/annurev.en.35.010190.001015
  11. Kost TA, Condreay JP, Jarvis DL: Baculovirus as versatile vectors for protein expression in insect and mammalian cells. Nat Biotechnol 23;567-575, 2005. https://doi.org/10.1038/nbt1095
  12. O'Reilly DR, Miller LK, Luckow VA: Baculovirus expression vectors: a laboratory manual. Oxford (UK): Oxford University Press; 1992.
  13. Lee MJ, Jin YH, Kim K, Choi Y, Kim HC, Park S: Expression of hepatitis B virus x protein in hepatocytes suppresses CD8 T cell activity. Immune Netw 10;126-134, 2010. https://doi.org/10.4110/in.2010.10.4.126
  14. Bai B, Lu X, Meng J, Hu Q, Mao P, Lu B, Chen Z, Yuan Z, Wang H: Vaccination of mice with recombinant baculovirus expressing spike or nucleocapsid protein of SARS-like coronavirus generates humoral and cellular immune responses. Mol Immunol 45;868-875, 2008. https://doi.org/10.1016/j.molimm.2007.08.010
  15. Strauss R, Huser A, Ni S, Tuve S, Kiviat N, Sow PS, Hofmann C, Lieber A: Baculovirus-based vaccination vectors allow for efficient induction of immune responses against plasmodium falciparum circumsporozoite protein. Mol Ther 15;193-202, 2007. https://doi.org/10.1038/sj.mt.6300008
  16. Abe T, Takahashi H, Hamazaki H, Miyano-Kurosaki N, Matsuura Y, Takaku H: Baculovirus induces an innate immune response and confers protection from lethal influenza virus infection in mice. J Immunol 171;1133-1139, 2003. https://doi.org/10.4049/jimmunol.171.3.1133
  17. Barsoum J, Brown R, McKee M, Boyce FM: Efficient transduction of mammalian cells by a recombinant baculovirus having the vesicular stomatitis virus G glycoprotein. Hum Gene Ther 8;2011-2018, 1997. https://doi.org/10.1089/hum.1997.8.17-2011
  18. Pieroni L, Maione D, La Monica N: In vivo gene transfer in mouse skeletal muscle mediated by baculovirus vectors. Hum Gene Ther 12;871-881, 2001. https://doi.org/10.1089/104303401750195845
  19. Facciabene A, Aurisicchio L, La Monica N: Baculovirus vectors elicit antigen-specific immune responses in mice. J Virol 78;8663-8672, 2004. https://doi.org/10.1128/JVI.78.16.8663-8672.2004
  20. Park SH, Chang J, Yang SH, Kim HJ, Kwak HH, Kim BM, Lee SH: Enhancement of antigen-specific antibody and CD8(+) T cell responses by codelivery of IL-12-encapsulated microspheres in protein and peptide vaccination. Immune Netw 7;186-196, 2007. https://doi.org/10.4110/in.2007.7.4.186
  21. Lee JB, Chang J: CD43 Expression regulated by IL-12 signaling is associated with survival of CD8 T cells. Immune Netw 10;153-163, 2010. https://doi.org/10.4110/in.2010.10.5.153
  22. Brandtzaeg P: Role of secretory antibodies in the defence against infections. Int J Med Microbiol 293;3-15, 2003. https://doi.org/10.1078/1438-4221-00241
  23. Hancock GE, Speelman DJ, Heers K, Bortell E, Smith J, Cosco C: Generation of atypical pulmonary inflammatory responses in BALB/c mice after immunization with the native attachment (G) glycoprotein of respiratory syncytial virus. J Virol 70;7783-7791, 1996.
  24. Srikiatkhachorn A, Braciale TJ: Virus-specific CD8+ T lymphocytes downregulate T helper cell type 2 cytokine secretion and pulmonary eosinophilia during experimental murine respiratory syncytial virus infection. J Exp Med 186;421-432, 1997. https://doi.org/10.1084/jem.186.3.421
  25. Stevens WW, Kim TS, Pujanauski LM, Hao X, Braciale TJ: Detection and quantitation of eosinophils in the murine respiratory tract by flow cytometry. J Immunol Methods 327;63-74, 2007. https://doi.org/10.1016/j.jim.2007.07.011
  26. Chang J: Current progress on development of respiratory syncytial virus vaccine. BMB Rep 44;232-237, 2011. https://doi.org/10.5483/BMBRep.2011.44.4.232
  27. Alwan WH, Kozlowska WJ, Openshaw PJ: Distinct types of lung disease caused by functional subsets of antiviral T cells. J Exp Med 179;81-89, 1994. https://doi.org/10.1084/jem.179.1.81
  28. Lin YH, Lee LH, Shih WL, Hu YC, Liu HJ: Baculovirus surface display of sigmaC and sigmaB proteins of avian reovirus and immunogenicity of the displayed proteins in a mouse model. Vaccine 26;6361-6367, 2008. https://doi.org/10.1016/j.vaccine.2008.09.008
  29. Yoshida S, Kondoh D, Arai E, Matsuoka H, Seki C, Tanaka T, Okada M, Ishii A: Baculovirus virions displaying Plasmodium berghei circumsporozoite protein protect mice against malaria sporozoite infection. Virology 316;161-170, 2003. https://doi.org/10.1016/j.virol.2003.08.003
  30. Yang DG, Chung YC, Lai YK, Lai CW, Liu HJ, Hu YC: Avian influenza virus hemagglutinin display on baculovirus envelope: cytoplasmic domain affects virus properties and vaccine potential. Mol Ther 15;989-996, 2007. https://doi.org/10.1038/mt.sj.6300131
  31. Hu YC: Baculovirus as a highly efficient expression vector in insect and mammalian cells. Acta Pharmacol Sin 26;405-416, 2005. https://doi.org/10.1111/j.1745-7254.2005.00078.x
  32. Gronowski AM, Hilbert DM, Sheehan KC, Garotta G, Schreiber RD: Baculovirus stimulates antiviral effects in mammalian cells. J Virol 73;9944-9951, 1999.
  33. Abe T, Kaname Y, Wen X, Tani H, Moriishi K, Uematsu S, Takeuchi O, Ishii KJ, Kawai T, Akira S, Matsuura Y: Baculovirus induces type I interferon production through toll-like receptor-dependent and -independent pathways in a cell-type-specific manner. J Virol 83;7629-7640, 2009. https://doi.org/10.1128/JVI.00679-09
  34. Tripp RA, Oshansky C, Alvarez R: Cytokines and respiratory syncytial virus infection. Proc Am Thorac Soc 2;147-149, 2005. https://doi.org/10.1513/pats.200502-014AW
  35. Kolls JK, Linden A: Interleukin-17 family members and inflammation. Immunity 21;467-476, 2004. https://doi.org/10.1016/j.immuni.2004.08.018
  36. Korn T, Bettelli E, Oukka M, Kuchroo VK: IL-17 and Th17 Cells. Annu Rev Immunol 27;485-517, 2009. https://doi.org/10.1146/annurev.immunol.021908.132710
  37. Yeh N, Glosson NL, Wang N, Guindon L, McKinley C, Hamada H, Li Q, Dutton RW, Shrikant P, Zhou B, Brutkiewicz RR, Blum JS, Kaplan MH: Tc17 cells are capable of mediating immunity to vaccinia virus by acquisition of a cytotoxic phenotype. J Immunol 185;2089-2098, 2010. https://doi.org/10.4049/jimmunol.1000818
  38. McKinstry KK, Strutt TM, Buck A, Curtis JD, Dibble JP, Huston G, Tighe M, Hamada H, Sell S, Dutton RW, Swain SL: IL-10 deficiency unleashes an influenza-specific Th17 response and enhances survival against high-dose challenge. J Immunol 182;7353-7363, 2009. https://doi.org/10.4049/jimmunol.0900657
  39. Newcomb DC, Zhou W, Moore ML, Goleniewska K, Hershey GK, Kolls JK, Peebles RS Jr: A functional IL-13 receptor is expressed on polarized murine CD4+ Th17 cells and IL-13 signaling attenuates Th17 cytokine production. J Immunol 182;5317-5321, 2009. https://doi.org/10.4049/jimmunol.0803868
  40. Schnyder-Candrian S, Togbe D, Couillin I, Mercier I, Brombacher F, Quesniaux V, Fossiez F, Ryffel B, Schnyder B: Interleukin-17 is a negative regulator of established allergic asthma. J Exp Med 203;2715-2725, 2006. https://doi.org/10.1084/jem.20061401
  41. Jaffar Z, Ferrini ME, Herritt LA, Roberts K: Cutting edge: lung mucosal Th17-mediated responses induce polymeric Ig receptor expression by the airway epithelium and elevate secretory IgA levels. J Immunol 182;4507-4511, 2009. https://doi.org/10.4049/jimmunol.0900237

Cited by

  1. Advances in and the potential of vaccines for respiratory syncytial virus vol.7, pp.4, 2012, https://doi.org/10.1586/17476348.2013.814409
  2. Effect of respiratory syncytial virus on the growth of hepatocellular carcinoma cell-lines vol.48, pp.10, 2015, https://doi.org/10.5483/bmbrep.2015.48.10.268
  3. Crimean-Congo Hemorrhagic Fever Virus Gn Bioinformatic Analysis and Construction of a Recombinant Bacmid in Order to Express Gn by Baculovirus Expression System vol.8, pp.11, 2012, https://doi.org/10.5812/jjm.25502
  4. Respiratory syncytial virus vaccines: an update on those in the immediate pipeline vol.11, pp.11, 2012, https://doi.org/10.2217/fmb-2016-0106
  5. Recombinant baculovirus-based vaccine expressing M2 protein induces protective CD8+ T-cell immunity against respiratory syncytial virus infection vol.55, pp.11, 2012, https://doi.org/10.1007/s12275-017-7306-6
  6. Immunological Features of Respiratory Syncytial Virus-Caused Pneumonia—Implications for Vaccine Design vol.18, pp.3, 2012, https://doi.org/10.3390/ijms18030556
  7. Recombinant baculovirus expressing the FrC-OVA protein induces protective antitumor immunity in an EG7-OVA mouse model vol.13, pp.1, 2019, https://doi.org/10.1186/s13036-019-0207-y